Alicia C. Olivo Sells 5,175 Shares of NeoGenomics, Inc. (NASDAQ:NEO) Stock

NeoGenomics, Inc. (NASDAQ:NEO) General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the transaction, the general counsel now directly owns 37,129 shares in the company, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

NeoGenomics Price Performance

Shares of NEO opened at $15.36 on Thursday. NeoGenomics, Inc. has a 1 year low of $12.77 and a 1 year high of $21.22. The business’s 50 day simple moving average is $14.66 and its 200-day simple moving average is $14.82. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.04. The business had revenue of $167.80 million for the quarter, compared to analysts’ expectations of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.06) EPS. Equities research analysts anticipate that NeoGenomics, Inc. will post -0.17 EPS for the current year.

Institutional Trading of NeoGenomics

Several hedge funds have recently modified their holdings of the company. Edgestream Partners L.P. purchased a new stake in NeoGenomics during the 1st quarter valued at $1,894,000. Bellevue Group AG purchased a new stake in NeoGenomics during the 1st quarter valued at $14,872,000. First Light Asset Management LLC raised its holdings in NeoGenomics by 14.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,782,561 shares of the medical research company’s stock valued at $52,464,000 after buying an additional 480,396 shares during the period. Blue Trust Inc. raised its holdings in NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after buying an additional 987 shares during the period. Finally, Sei Investments Co. raised its holdings in NeoGenomics by 152.6% during the 2nd quarter. Sei Investments Co. now owns 263,761 shares of the medical research company’s stock valued at $3,658,000 after buying an additional 159,350 shares during the period. 98.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NEO has been the topic of a number of analyst reports. Benchmark reaffirmed a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a research report on Tuesday, September 24th. Stephens reissued an “overweight” rating and issued a $19.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Finally, Needham & Company LLC restated a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Wednesday, November 6th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $20.25.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.